LEMAITRE VASCULAR, INC. (LMAT) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value 14.88×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | 14.88× | Operating income ÷ reported interest expense. $77.32M ÷ $5.20M ≈ 14.88× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 15.41M USD | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 7.86M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 77.32M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 5.20M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $15.41M | (m) | $7.86M | $77.32M | $5.20M | (m) | (m) | 14.88× | Reported |
| 2026-03-31 | $14.10M | (m) | $7.87M | $73.06M | $5.19M | (m) | (m) | 14.07× | Reported |
| 2025-12-31 | $14.14M | $249.60M | $7.83M | $67.91M | $5.18M | 5.66% | 3.14% | 13.10× | Reported |
| 2025-09-30 | $14.22M | (m) | $7.47M | $61.93M | $4.09M | (m) | (m) | 15.14× | Reported |
| 2025-06-30 | $14.91M | (m) | $7.34M | $54.77M | $2.79M | (m) | (m) | 19.60× | Reported |
| 2025-03-31 | $15.65M | (m) | $7.00M | $53.01M | $1.50M | (m) | (m) | 35.46× | Reported |
| 2024-12-31 | $15.65M | $219.86M | $6.57M | $52.26M | $205.00K | 7.12% | 2.99% | 254.91× | Reported |
| 2024-09-30 | $16.38M | $213.03M | $6.23M | $49.61M | (m) | 7.69% | 2.93% | (m) | (m) |
| 2024-06-30 | $16.95M | $205.62M | $5.94M | $45.64M | (m) | 8.24% | 2.89% | (m) | (m) |
| 2024-03-31 | $17.18M | $199.89M | $5.64M | $40.71M | (m) | 8.60% | 2.82% | (m) | (m) |
| 2023-12-31 | $16.97M | $193.48M | $5.32M | $36.71M | $0.00 | 8.77% | 2.75% | (m) | Reported |
| 2023-09-30 | $16.17M | (m) | $4.60M | $33.47M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $15.41M | $177.17M | $4.47M | $30.44M | (m) | 8.70% | 2.52% | (m) | (m) |
| 2023-03-31 | $14.24M | $169.16M | $4.30M | $26.77M | (m) | 8.42% | 2.54% | (m) | (m) |
| 2022-12-31 | $13.29M | $161.65M | $4.17M | $26.83M | $0.00 | 8.22% | 2.58% | (m) | Reported |
| 2022-09-30 | $13.20M | $160.20M | $4.38M | $28.16M | $526.00K | 8.24% | 2.73% | 53.54× | Reported |
| 2022-06-30 | $12.58M | $159.54M | $3.99M | $31.09M | $1.15M | 7.89% | 2.50% | 27.10× | Reported |
| 2022-03-31 | $11.89M | $158.10M | $3.72M | $36.41M | $1.64M | 7.52% | 2.35% | 22.17× | Reported |
| 2021-12-31 | $11.80M | $154.42M | $3.48M | $36.42M | $2.22M | 7.64% | 2.25% | 16.42× | Reported |
| 2021-09-30 | $11.21M | $152.47M | $3.35M | $37.67M | $2.27M | 7.35% | 2.19% | 16.59× | Reported |
| 2021-06-30 | $10.46M | $150.52M | $3.24M | $38.61M | $2.32M | 6.95% | 2.15% | 16.67× | Reported |
| 2021-03-31 | $9.95M | $134.70M | $3.17M | $32.38M | $1.89M | 7.39% | 2.35% | 17.16× | Reported |
| 2020-12-31 | $10.10M | $129.37M | $3.02M | $28.79M | $1.31M | 7.81% | 2.34% | 21.98× | Reported |
| 2020-09-30 | $9.73M | $121.99M | $2.82M | $24.17M | (m) | 7.98% | 2.31% | (m) | (m) |
| 2020-06-30 | $9.91M | $114.67M | $2.78M | $20.06M | (m) | 8.64% | 2.43% | (m) | (m) |
| 2020-03-31 | $10.03M | $119.30M | $2.67M | $21.10M | (m) | 8.41% | 2.24% | (m) | (m) |
| 2019-12-31 | $9.28M | $117.23M | $2.64M | $21.18M | (m) | 7.91% | 2.25% | (m) | (m) |
| 2019-09-30 | $9.12M | $115.45M | $2.65M | $23.45M | (m) | 7.90% | 2.30% | (m) | (m) |
| 2019-06-30 | $8.88M | $110.52M | $2.53M | $22.16M | (m) | 8.04% | 2.29% | (m) | (m) |
| 2019-03-31 | $8.61M | $108.05M | $2.47M | $27.78M | (m) | 7.97% | 2.29% | (m) | (m) |
| 2018-12-31 | $8.20M | $105.57M | $2.35M | $28.21M | $2.00K | 7.76% | 2.23% | 14104.50× | Reported |
| 2018-09-30 | $7.43M | $103.33M | $2.21M | $27.34M | (m) | 7.19% | 2.13% | (m) | (m) |
| 2018-06-30 | $7.16M | $103.99M | $2.55M | $27.78M | (m) | 6.88% | 2.46% | (m) | (m) |
| 2018-03-31 | $6.80M | $102.72M | $2.39M | $21.77M | (m) | 6.62% | 2.33% | (m) | (m) |
| 2017-12-31 | $6.64M | $100.87M | $2.26M | $21.10M | $21.00K | 6.58% | 2.24% | 1004.90× | Reported |
| 2017-09-30 | $6.58M | $98.00M | $2.33M | $18.69M | (m) | 6.71% | 2.38% | (m) | (m) |
| 2017-06-30 | $6.35M | $96.40M | $1.98M | $18.98M | (m) | 6.59% | 2.05% | (m) | (m) |
| 2017-03-31 | $6.35M | $93.03M | $1.84M | $17.23M | $14.00K | 6.83% | 1.97% | 1230.64× | Reported |
| 2016-12-31 | $6.14M | $89.15M | $1.68M | $16.34M | $14.00K | 6.89% | 1.88% | 1166.86× | Reported |
| 2016-09-30 | $6.19M | $86.35M | $1.53M | $15.52M | (m) | 7.17% | 1.77% | (m) | (m) |
| 2016-06-30 | $6.08M | $82.16M | $1.48M | $13.49M | (m) | 7.39% | 1.80% | (m) | (m) |
| 2016-03-31 | $5.77M | $79.66M | $1.43M | $12.50M | (m) | 7.25% | 1.79% | (m) | (m) |
| 2015-12-31 | $5.48M | $78.35M | $1.42M | $11.51M | (m) | 6.99% | 1.82% | (m) | (m) |
| 2015-09-30 | $4.99M | $76.55M | $1.41M | $11.16M | (m) | 6.51% | 1.84% | (m) | (m) |
| 2015-06-30 | $4.67M | $75.03M | $1.37M | $9.69M | (m) | 6.23% | 1.82% | (m) | (m) |
| 2015-03-31 | $4.48M | $73.29M | $1.35M | $8.88M | (m) | 6.11% | 1.84% | (m) | (m) |
| 2014-12-31 | $4.67M | $71.10M | $1.30M | $6.34M | $5.00K | 6.57% | 1.83% | 1268.00× | Reported |
| 2014-09-30 | $4.99M | $70.33M | $1.27M | $4.77M | $0.00 | 7.10% | 1.80% | (m) | Reported |
| 2014-06-30 | $5.18M | $68.13M | $1.24M | $3.70M | $0.00 | 7.61% | 1.82% | (m) | Reported |
| 2014-03-31 | $5.31M | $65.92M | $1.25M | $3.16M | (m) | 8.06% | 1.90% | (m) | (m) |
| 2013-12-31 | $5.24M | $64.55M | $1.25M | $4.52M | $12.00K | 8.12% | 1.94% | 376.50× | Reported |
| 2013-09-30 | $5.40M | $61.43M | $1.24M | $4.28M | (m) | 8.79% | 2.02% | (m) | (m) |
| 2013-06-30 | $5.36M | $59.78M | $1.24M | $4.50M | (m) | 8.97% | 2.07% | (m) | (m) |
| 2013-03-31 | $5.23M | $58.19M | $1.23M | $4.51M | (m) | 8.99% | 2.11% | (m) | (m) |
| 2012-12-31 | $5.09M | $56.73M | $1.21M | $4.24M | $1.00K | 8.98% | 2.14% | 4240.00× | Reported |
| 2012-09-30 | $4.67M | $55.34M | $1.19M | $4.14M | (m) | 8.44% | 2.14% | (m) | (m) |
| 2012-06-30 | $4.38M | $56.26M | $1.10M | $5.13M | (m) | 7.79% | 1.95% | (m) | (m) |
| 2012-03-31 | $4.29M | $57.02M | $1.10M | $4.57M | (m) | 7.52% | 1.92% | (m) | (m) |
| 2011-12-31 | $4.42M | $57.69M | $1.10M | $3.69M | (m) | 7.67% | 1.90% | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $5.49M | $56.06M | $967.00K | $4.01M | $5.00K | 9.79% | 1.72% | 803.00× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $5.91M | $50.91M | $985.00K | $1.95M | $26.00K | 11.61% | 1.93% | 74.96× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NovoCure Ltd (NVCR) | $1.886B | -11.87 | |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |